EGFR and non-small cell lung carcinoma: As the development of the molecular biology, the discovery of epidermal growth factor receptor (EGFR) and the emergence of small molecular tyrosine kinase inhibitors (TKIs) targeting EGFR mutations, such as gefitinib and erlotinib, have revolutionized the treatment of advanced NSCLC (4).